anonymous
Guest
anonymous
Guest
Novo will be losing ALOT of key people soon, and Lilly is ramping up production for Mounjaro AND Zepbound way faster. 3Q and 4Q numbers will reveal a slowing/miss of # for Semaglutide products, where Lilly will exceed.
Not saying this is forever, but next 6 months could move stock down to $105-$110 range, based on P/E ratio expectations.
Not saying this is forever, but next 6 months could move stock down to $105-$110 range, based on P/E ratio expectations.